Navigation Links
ThromboGenics NV: Business Update
Date:5/14/2009

associated with current anti-coagulant therapy.

Patient recruitment for this trial is on track and it is anticipated that this study will conclude by the end of 2010.

TB-403 - Anti-cancer: Partnership with Roche progressing well - Phase Ib trial results expected by the end of 2009. In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). In January, 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

The clinical development of TB-403 is also progressing well with the results of a Phase Ib trial expected by the end of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

Microplasmin for Vascular Disease - Initial partnering discussions. After the encouraging Phase II results presented last year, ThromboGenics is continuing to look for a partner to continue the further development of microplasmin for the treatment of stroke.

Pre-Clinical Highlights

Anti-VPAC - EUR3.2 million Grant Awarded to ThromboGenics for the continued development of Anti-VPAC for the treatment of thrombocytopenia - At the end of February 2009, ThromboGenics was awarded a grant of up to EUR3.2 million for the continued development of its Anti-VPAC1 (Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase-Activating Peptide Receptor 1) antibody for the treatment of thrombocytopenia (low platelet count) after chemotherapy.

The grant was received from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is based on the successful completion
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... sheet of carbon, can be randomly decorated with oxygen ... could have a significant impact on the chemical, pharmaceutical ... an ultra-strong, non-corrosive coating for a wide range of ... used to paint various surfaces ranging from glass to ... treatment, the resulting coatings behave like graphite in terms ...
(Date:9/11/2014)... 2014 The Registration Committee today ... now open for Pittcon 2015, the world’s largest ... event will be held March 8-12, 2015, at ... , The discounted registration fee of $175 ... 2/20/2015). This affordable price includes unlimited week-long access ...
(Date:9/11/2014)... , Sept. 11, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), announces that it intends to ... US$ 2 million for funding its preclinical development ... Company Limited, ("Biohaven"). The Company is ... to 20 million common shares at a price ...
(Date:9/11/2014)... Awarded annually by Germany’s Design ... internationally recognized quality label for excellent design. METTLER ... coveted Red Dot award in recognition ... Powder Dispenser (HPD). , The Quantos Handheld ... and ease-of-use to applications involving free-flowing powders. Forget ...
Breaking Biology Technology:Graphene paints a corrosion-free future 2Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4METTLER TOLEDO Handheld Powder Receives Red Dot Award for Product Design 2
... Enanta Pharmaceuticals, Inc. announced today that its lead ... inhibitor program, EDP-239, has been recognized on Windhover,s list ... to Watch." EDP-239 was chosen by independent experts at ... a clinically-validated target, is a non-structural viral protein that ...
... at deCODE Genetics and academic collaborators from Iceland, The Netherlands, ... today report the discovery of a variant in the sequence ... cell carcinoma of the skin (BCC), as well as prostate ...  The study was done in collaboration with Illumina, Inc., and ...
... Sept. 23, 2011 Citizens Bank today announced that ... a major expansion by The Wistar Institute that includes ... historic facility at 36th and Spruce streets in University ... an international leader in basic biomedical research, particularly cancer ...
Cached Biology Technology:Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 2Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 3deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 2deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 3Citizens Bank Provides $70 Million in Financing Toward $100 Million Expansion of The Wistar Institute 2
(Date:9/12/2014)... come under attack from a pathogen, they sometimes respond ... the attack, committing "cell suicide" to thwart further damage ... small, often microscopic, spots or lesions on the plant. ... understand how the plant regulates this "spotty" defense mechanism ... Researchers at North Carolina State University have identified a ...
(Date:9/12/2014)... and POINT ROBERTS, Washington , September 12, ... http://www.investorideas.com ) a global news source covering leading sectors including ... on the September 9 th launch of Apple Pay, ... Intelligence, Janice Kephart , founder of the Secure Identity ... of NXT-ID, Inc, (NASDAQ: NXTD ) a company ...
(Date:9/11/2014)... Amsterdam, NL, 11 September 2014 Patients with ... preparation and ingestion, which could contribute to poor ... Published studies have also suggested that PD is ... control groups. A report published in the ... in patients with mild-to-moderate PD, finding that the ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5Few mild-to-moderate Parkinson's disease patients suffer from malnutrition, yet almost one-third are at risk 2
... Study of Hepatitis C (PEDS-C) trial reveals that children ... display significant changes in height, weight, body mass index ... issue of Hepatology , a journal of the ... that most growth-related side effects are reversible with cessation ...
... New Rochelle, NY, August 9, 2012Despite criticism from Congressional ... its Rim of the Pacific (RIMPAC) 2012 international maritime ... 50% biofuels blend. The Navy contends that renewable energy ... play in enhancing national security and energy independence. Tom ...
... University researchers are teaming up with Coastal Carolina University ... along the Savannah River to gather data for the ... and transmit real-time information about the quality and quantity ... project leaders Gene Eidson, director of Clemson,s Institute of ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2US Navy defends renewable fuels strategy in Industrial Biotechnology Journal 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
... cleanup kit is a sample preparation kit ... by removal of detergents, phenolic compounds, salts, ... concentrates dilute samples. The kit procedure involves ... mammalian tissue or cells, plant leaves, E. ...
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Biology Products: